Enabling accelerated vaccine roll-out for Public Health Emergencies of International Concern (PHEICs): Novel Oral Polio Vaccine type 2 (nOPV2) experience.
Emergency use listing
Novel oral poliovirus vaccine
Poliovirus
Public health emergency of international concern
Vaccine
Journal
Vaccine
ISSN: 1873-2518
Titre abrégé: Vaccine
Pays: Netherlands
ID NLM: 8406899
Informations de publication
Date de publication:
06 04 2023
06 04 2023
Historique:
received:
24
08
2021
revised:
17
01
2022
accepted:
09
02
2022
medline:
3
4
2023
pubmed:
22
3
2022
entrez:
21
3
2022
Statut:
ppublish
Résumé
To address the evolving risk of circulating vaccine-derived poliovirus type 2 (cVDPV2), Global Polio Eradication Initiative (GPEI) partners are working closely with countries to deploy an additional innovative tool for outbreak response - novel oral polio vaccine type 2 (nOPV2). The World Health Organization's (WHO) Prequalification program issued an Emergency Use Listing (EUL) recommendation for nOPV2 on 13 November 2020. The WHO's EUL procedure was created to assess and list unlicensed vaccines, therapeutics and diagnostics to enable their use in response to a Public Health Emergency of International Concern (PHEIC). nOPV2 was the first vaccine to receive an EUL, paving the way for other emergency vaccines. In this report, we summarise the pathway for nOPV2 roll-out under EUL.
Identifiants
pubmed: 35307230
pii: S0264-410X(22)00195-5
doi: 10.1016/j.vaccine.2022.02.050
pmc: PMC10109087
pii:
doi:
Substances chimiques
Poliovirus Vaccine, Oral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
A122-A127Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
Copyright © 2022. Published by Elsevier Ltd.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
J Virol. 2015 Oct 14;90(1):317-31
pubmed: 26468545
Cell Host Microbe. 2020 May 13;27(5):736-751.e8
pubmed: 32330425
J Infect Dis. 2022 Aug 24;226(2):287-291
pubmed: 33367918
Lancet Infect Dis. 2019 Oct;19(10):1121-1128
pubmed: 31350192
Lancet. 2018 Dec 8;392(10163):2425
pubmed: 30527404
Annu Rev Microbiol. 2005;59:587-635
pubmed: 16153180
Lancet. 2019 Jul 13;394(10193):148-158
pubmed: 31174831
PLoS One. 2018 Dec 28;13(12):e0208336
pubmed: 30592720
NPJ Vaccines. 2020 Mar 20;5(1):26
pubmed: 32218998
Lancet Infect Dis. 2017 Oct;17(10):1069-1079
pubmed: 28693854
Future Microbiol. 2019 Oct;14:1321-1330
pubmed: 31482728
Science. 2020 Apr 24;368(6489):401-405
pubmed: 32193361
Lancet. 2021 Jan 2;397(10268):39-50
pubmed: 33308429
Curr Opin Infect Dis. 2020 Oct;33(5):404-410
pubmed: 32773500
Lancet. 2021 Jan 2;397(10268):27-38
pubmed: 33308427